This is a repository copy of *Immunogenicity of Self Tumor Associated Antigens Is Enhanced Through Protein Truncation*.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/101999/

Version: Accepted Version

**Proceedings Paper:**

© 2016, Author(s). This is an author produced version of a paper published in Molecular Therapy. Uploaded in accordance with the publisher’s self-archiving policy.

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Immunogenicity of Self Tumor Associated Antigens Is Enhanced Through Protein Truncation
Tim Kottke; Kevin G. Shim; Laura Evgin; Vanesa Alonso-Camino; Shane Zaidi; Rosa Maria Diaz; Jose Pulido; Jill Thompson; Karishma R. Rajani; Amanda Huff; Elizabeth Ilett; Hardev Pandha; Kevin Harrington; Peter Selby; Alan Melcher; Richard Vile.

We showed previously that expressing tumor-associated antigens (TAA) from Vesicular Stomatitis Virus eradicates established tumors. We show here that truncation of TAA expressed from VSV can occur to preserve the ability of the virus to replicate efficiently. We observed that truncation of VSV-expressed TAA affects the processing of the antigen, causing a bias towards an IL-17 anti-tumor response which was raised by cumulative signaling from different types of APC, each presenting specific, truncated antigens. Whereas processing of full length, self-TAA invoked an IFN-\(\text{\textgamma}\) based, CD8+ dependent response, truncated versions of the same self-TAA (likely to be poorly and incompletely folded) were processed through a class II-dependent pathway, and invoked an IL-17 based response. Significantly, the IL-17-mediated anti tumor response was both more therapeutic, and durable, than the response against full length self-TAA. These data show that the type/potency of anti-tumor immune responses against self-TAA can be manipulated \textit{in vivo} through the nature of the self protein (full length or truncated), inclusion of multiple TAA to recruit the optimal combination of APC, and the resultant skewing of the T cell response to either an IFN-\(\gamma\) or IL-17 producing phenotype. Therefore, in addition to generation of neoantigens through sequence mutation, immunological tolerance against self-TAA can be broken through manipulation of protein integrity, allowing for rational design of better self immunogens for cancer immunotherapy.